false
0001641631
0001641631
2024-02-12
2024-02-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): February 12, 2024
Beyond
Air, Inc.
(Exact
Name of Registrant as Specified in Charter)
| Delaware |
|
001-38892 |
|
47-3812456 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
900
Stewart Avenue, Suite 301
Garden
City, NY 11530
(Address
of Principal Executive Offices and Zip Code)
(516)
665-8200
Registrant’s
Telephone Number, Including Area Code
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| |
☐ |
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
|
| |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $.0001 per share |
|
XAIR |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Conditions.
On
February 12, 2024, Beyond Air, Inc. (the “Company”) issued a press release announcing financial results for the third quarter
of its Fiscal Year 2024. A copy of the press release is furnished hereto as Exhibit 99.1 hereto.
This
information, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933,
except as shall be expressly set forth by specific reference in such filing.
Item
8.01. Other Events.
On
February 14, 2024, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with Jeff Myers, M.D., Ph.D,
the Company’s Chief Medical Officer, in connection with Dr. Myers’s transition from his position as the Company’s Chief
Medical Officer to a consultant. Dr. Myers’s last day of employment is on or about February 16, 2024. The Consulting Agreement
sets forth Dr. Myers’s consideration as a consultant and the terms pursuant to which Dr. Myers will assist the Company in the transition
of his roles and continue in a consulting capacity until July 31, 2024, beginning as of the effective date of the Consulting Agreement
(the “Consulting Period”). During the Consulting Period, Dr. Myers will continue to provide services to the Company on a
non-exclusive basis, unless the Consulting Agreement is earlier terminated by either party in accordance with its terms. In exchange
for his services, the Company will pay Dr. Myers a fee of $16,000 per month during the Consulting Period.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
BEYOND
AIR, Inc. |
| |
|
| Date:
February 16, 2024 |
By: |
/s/
Steven A. Lisi |
| |
Name: |
Steven
A. Lisi |
| |
Title |
Chief
Executive Officer |
Exhibit
99.1
Beyond
Air® Reports Financial Results
for
Third Quarter of Fiscal Year 2024
Commercial
demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand
PMA
supplement for the expansion of LungFit PH label to include cardiac surgery accepted for filing and under substantive review by the FDA
U.S.
pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway; trial will extend over two seasons; the
pivotal study remains on track for Winter 2025/26
Phase
1 Study evaluating Beyond Cancer’s ultra-high concentration nitric oxide (UNO) in advanced, R/R unresectable, primary or metastatic
cutaneous and subcutaneous solid tumors cleared the first cohort with no reported dose limiting toxicities
Reiterated
FY 2025 revenue guidance of $12 million to $16 million
Conference
call scheduled for 4:30 p.m. ET today, February 12th
GARDEN
CITY, N.Y., Feb. 12, 2024 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”),
a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide
(NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate
Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced its financial results for the fiscal quarter ended December 31, 2023.
“In
the third quarter of fiscal year 2024, we reported solid sequential revenue growth of more than 60% compared with the second quarter.
This increasing demand for our current LungFit PH system was seen even as we prepared to launch a key software update. As our inventory
of upgraded LungFit PH grows, we expect to be able to meet accelerating demand over the next several quarters. This positive commercial
traction gives us even more confidence in hitting our fiscal year 2025 sales guidance of $12 to $16 million,” said Steve Lisi,
Chairman and Chief Executive Officer of Beyond Air. “The PMA supplement for the expansion of the LungFit PH label to include cardiac
surgery was accepted for filing by the FDA in late-December and is currently under substantive review. FDA approval for this application
should generate even broader use of LungFit PH in U.S. hospitals.”
Recent
Highlights and Upcoming Milestones
| |
◌ |
Commercial
demand continues to increase for the LungFit PH, as evidenced by a more than 100% increase in filters shipped quarter over quarter |
| |
■ |
This
growth trend is expected to continue following the implementation of a much-awaited software update approved by the FDA in September
2023 |
| |
◌ |
CE
Mark is expected to be received in first half calendar 2024 |
| |
◌ |
PMA
supplement for a cardiac surgery label expansion accepted for filing and under substantive review by the FDA |
| |
◌ |
Revenue
guidance of $12 - $16 million reiterated for the fiscal year ending March 31, 2025 |
| |
◌ |
Sites
opened for a U.S. pilot trial for patients hospitalized with viral community-acquired pneumonia (VCAP) |
| |
■ |
Randomized,
double-blind, placebo-controlled trial in 50 patients at up to 10 sites |
| |
■ |
Top
line data expected mid-year 2025 from VCAP study as trial is expected to extend over two seasons |
| |
◌ |
Expect
to initiate a pivotal trial in the 2025/2026 pneumonia season |
| |
◌ |
Plan
to initiate a U.S. trial for patients with nontuberculous mycobacteria (NTM) in calendar year 2025, pending discussion with the FDA
|
| |
◌ |
COPD
pilot trial on hold due to strategic prioritization |
| ● |
Beyond
Cancer - Solid Tumor Program |
| |
◌ |
The
ongoing Phase 1 Study evaluating UNO in advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous
solid tumors has cleared the first cohort of 25,000 ppm single dose UNO by the Safety Review Committee, with no reported dose limiting
toxicities |
| |
■ |
Enrollment
is underway for the 50,000 ppm cohort of the Phase 1 Study |
| |
■ |
Preparations
are being made to enter the Phase Ib portion of the study where UNO is anticipated to be dosed in combination with anti-PD1 |
| |
◌ |
First-in-human
data presented at the Society for Immunotherapy Conference (SITC) in November 2023 show that a single intratumoral injection of UNO
therapy for 5 minutes was safe and well tolerated in patients and showed upregulation of cytotoxic T-cells, T-central memory cells,
M1 macrophages, and dendritic cells while downregulating T-regulatory cells and mononuclear-myeloid-derived suppressor cells (M-MDSC) |
| ● |
Autism
Spectrum Disorder (ASD) Program |
| |
◌ |
Plan
to initiate a first-in-human study for treatment of ASD in 2025 |
| |
◌ |
Published
pre-clinical data by Hebrew University of Jerusalem (HUJI) in the scientific journal Nitric Oxide in September 2023 which show that
the partial inhibition of nNOS reversed the manifestations of ASD phenotype, and reversed nitrosative stress. |
| |
◌ |
Duncan
Fatkin, Chief Commercial Officer, to leave the company on March 31, 2024; the Company has initiated an executive search for a replacement
and will provide updates as appropriate |
Financial
Results for the Fiscal Quarter Ended December 31, 2023
Revenues
for the three months ended December 31, 2023 were $0.4 million compared to zero for the quarter ended December 31, 2022. Cost of revenue
of $0.7 million was recognized for the three months ended December 31, 2023, compared to $0.1 million for the three months ended December
31, 2022.
Research
and development expenses for the three months ended December 31, 2023 were $6.8 million as compared to $5.0 million for the three months
ended December 31, 2022. The increase of $1.8 million was due primarily to an increase in development costs associated with the pipeline.
General
and administrative expenses for the three months ended December 31, 2023 and December 31, 2022 were $9.8 million and $8.9 million, respectively.
The $0.9 million increase was mainly due to increases in stock based compensation, headcount and salary inflation.
Net
loss attributed to common stockholders for the three months ended December 31, 2023, was ($16.2) million or a loss of ($0.50) per share,
basic and diluted. The Company’s net loss attributed to common stockholders for the three months ended December 31, 2022 was ($12.7)
million or a loss of ($0.43) per share, basic and diluted.
Total
cash burn in the quarter ended December 31, 2023, was $12.7 million, with payments required towards our VCAP study, development of our
Gen 2 device, continued in-human trials in Beyond Cancer and advances in our Autism program. The Company raised $5.5 million on its
ATM to partially offset the planned cash burn.
As
of December 31, 2023, the Company had cash, cash equivalents, marketable securities of $31.4 million as well as $5.2 million held on
deposit by our contract manufacturer.
Conference
Call & Webcast
Monday,
February 12th @ 4:30 PM ET
1-877-407-0784
(Domestic)
1-201-689-8560
(International)
Call
me - https://callme.viavid.com/viavid/?callme=true&passcode=13738837&h=true&info=company-email&r=true&B=6
Participants
can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event.
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1650835&tp_key=79566400ea
About
Beyond Air®, Inc.
Beyond
Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous
nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The
Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates
with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the
treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria
(NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated
to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate
of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in
the pre-clinical setting. For more information, visit www.beyondair.net.
About
Nitric Oxide
Nitric
Oxide is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological
functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently,
exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension
of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies
suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but
also against other diverse pathogens, including mycobacteria, viruses, fungi, yeast and parasites, and has the potential to eliminate
multi-drug resistant strains.
About
LungFit®*
Beyond
Air’s LungFit is a cylinder-free, phasic flow generator and delivery system and has been designated as a medical device by the
U.S. Food and Drug Administration (FDA). The ventilator compatible version of the device can generate NO from ambient air on demand for
delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure
NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements,
improving overall safety with the elimination of NO2 purging steps, and other benefits. LungFit can also deliver NO at concentrations
at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g. COVID-19, bronchiolitis)
and chronic, refractory lung infections in the home setting (e.g. NTM). With the elimination of cylinders, Beyond Air intends
to offer NO treatment in the home setting.
*
Beyond Air’s LungFit PH is approved for commercial use only in the United States of America to treat term and near-term neonates
with hypoxic respiratory failure. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational
use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
About
PPHN
Persistent
pulmonary hypertension of the newborn (PPHN) is a lethal condition and secondary to failure of normal circulatory transition at birth.
It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary
blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1000 live births (0.4–6.8/1000 live
births) with mortality rate ranging between 4–33%. This syndrome complicates the course of about 10% of infants with respiratory
failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator, is approved in dozens of countries to
improve oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation)
neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction
with ventilator support and other appropriate agents.
About
Viral Community-Acquired Pneumonia (VCAP)
In
adults, viruses have been identified as the causative agents in approximately 100 million cases of community-acquired pneumonia per year.
While viral pneumonia in adults is most commonly caused by rhinovirus, respiratory syncytial virus (RSV) and influenza virus, newly emerging
viruses (including SARS-CoV-1, SARS-CoV-2, avian influenza A, and H1N1 viruses) have been identified as pathogens contributing to the
overall burden of adult viral pneumonia. Patients aged 65 years or older are at particular risk for death from the disease, as are patients
with other underlying health conditions or weakened immune systems. There is no consensus regarding the use of antiviral drugs to treat
viral pneumonia, and specific preventative measures are currently limited to the influenza vaccine. Given that current treatment recommendations
are largely limited to supportive care, there is an unmet medical need for effective treatment options. NO may prove to be a treatment
as the impact on the lung should result in bronchodilation, reduction in inflammation and inhibition of the viral replication process.
About
NTM
NTM
infection is a rare and serious bacterial infection in the lungs causing debilitating pulmonary disease associated with high morbidity
and mortality. NTM infection is acquired by inhaling aerosolized bacteria from the environment, and can lead to NTM lung disease, a progressive
and chronic condition. According to the Cystic Fibrosis Foundation, 13% of U.S. cystic fibrosis patients had a positive culture for a
NTM species in 2017. NTM is considered an emerging public health concern worldwide because of its multi-drug antibiotic resistance. Current
treatment guidelines suggest a combination of multiple antibiotics dosed chronically for as long as two years. These complex, expensive
and invasive regimens have a poor record in the treatment of Mycobacterium abscessus complex (MABSC) and refractory Mycobacterium avium
complex (MAC) and have the potential to cause severe adverse events. Beyond Air’s system is designed to deliver 150 – 400
ppm NO to the lungs, and early data, including from the pilot study of the LungFit GO, indicate that this range of NO concentrations
could have a positive effect on patients infected with NTM.
About
Bronchiolitis
The
majority of hospital admissions of infants with bronchiolitis are caused by respiratory syncytial virus (RSV). RSV is a common and highly
transmissible virus that infects the respiratory tract of most children before their second birthday. While most infants with RSV present
with minor respiratory symptoms, a small percentage develop serious lower airway infections, termed bronchiolitis, which can become life-threatening.
The absence of treatment options for bronchiolitis limits the care of these sick infants to largely supportive measures. Beyond Air’s
system is designed to effectively deliver 150 – 400 ppm NO, for which preliminary studies indicate may eliminate bacteria, viruses,
fungi, and other microbes from the lungs.
About
Beyond Cancer, Ltd.
Beyond
Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing (UNO via
a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has
been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human
study is underway in patients with solid tumors. The Company is conducting preclinical studies of UNO in multiple solid tumor models
to inform additional treatment protocols.
For
more information, visit www.beyondcancer.com.
About
UNO Therapy for Solid Tumors
Cancer
is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths.
Current cancer treatment modalities generally include chemotherapy, immunotherapy, radiation, and/or surgery. UNO therapy is a completely
new approach to preventing relapse or metastatic disease. In vitro murine data show that local tumor ablation with UNO stimulates an
anti-tumor immune response in solid tumor cancer models. The Company believes that UNO has the potential to prevent relapse or metastatic
disease with as little as a single 5-minute treatment and with limited toxicity or off-target effects.
About
ASD
ASD
is a serious neurodevelopmental and behavioral disorder, and one of the most disabling conditions and chronic illnesses in children.
ASDs include a wide range of developmental disorders that share a core of neurobehavioral deficits manifested by abnormalities in social
interactions, deficits in communication, restricted interests, and repetitive behaviors. In 2023, the CDC reported that approximately
1 in 36 children in the U.S. is diagnosed with an ASD. On average, ASD costs an estimated $60,000 a year through childhood, with the
bulk of the costs in special services and lost wages related to increased demands on one or both parents. Mothers of children with ASD,
who tend to serve as the child’s case manager and advocate, are less likely to work outside the home. On average, they work fewer
hours per week and earn 56 percent less than mothers of children with no health limitations and 35 percent less than mothers of children
with other disabilities or disorders. The cost of caring for Americans with autism reached $268 billion in 2015 and is expected to rise
to $461 billion by 2025 in the absence of more-effective interventions and support across the life span.
Forward
Looking Statements
This
press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide
and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and
the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric
oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings,
business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,”
“expects,” “plans,” “anticipates,” “believes” “expects,” “intends,”
“looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions
and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should”
and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking
statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking
statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could
cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking
statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance.
Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking
statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies
and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may
not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may
never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials
of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval
for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators;
and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most
recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on
Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising,
these forward-looking statements, except as required by applicable law.
CONTACTS:
Investor
Relations contacts
Corey
Davis, Ph.D.
LifeSci
Advisors, LLC
Cdavis@lifesciadvisors.com
(212)
915-2577
Media
contacts
Kori-Ann
Taylor
Head
of Marketing
ktaylor@beyondair.net
++++++
BEYOND
AIR, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED BALANCE SHEETS
(amounts
in thousands, except share and per share data)
| | |
December 31,
2023 | | |
March 31,
2023 | |
| | |
(Unaudited) | | |
| |
| ASSETS | |
| | | |
| | |
| Current assets | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 7,971 | | |
$ | 29,158 | |
| Marketable securities | |
| 23,292 | | |
| 16,724 | |
| Restricted cash | |
| 5,250 | | |
| 10,129 | |
| Accounts receivable | |
| 294 | | |
| - | |
| Inventory, net | |
| 1,533 | | |
| 1,129 | |
| Grant receivable | |
| - | | |
| 420 | |
| Other current assets and prepaid expenses | |
| 1,099 | | |
| 1,850 | |
| Total current assets | |
| 39,439 | | |
| 59,410 | |
| Licensed right to use technology | |
| 1,478 | | |
| 1,632 | |
| Right-of-use lease assets | |
| 2,229 | | |
| 2,493 | |
| Property and equipment, net | |
| 8,551 | | |
| 5,003 | |
| Other assets | |
| 213 | | |
| 212 | |
| TOTAL ASSETS | |
$ | 51,911 | | |
$ | 68,749 | |
| | |
| | | |
| | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Accounts payable | |
$ | 3,220 | | |
$ | 2,016 | |
| Accrued expenses | |
| 7,882 | | |
| 16,613 | |
| Operating lease liability, current portion | |
| 408 | | |
| 376 | |
| Loans payable, current portion | |
| 130 | | |
| 775 | |
| Total current liabilities | |
| 11,641 | | |
| 19,780 | |
| | |
| | | |
| | |
| Operating lease liability, net | |
| 2,012 | | |
| 2,321 | |
| Long-term debt | |
| 14,380 | | |
| 120 | |
| Warrant liability | |
| 192 | | |
| - | |
| Derivative liability | |
| 214 | | |
| - | |
| Other long-term liabilities | |
| - | | |
| 4,500 | |
| Total liabilities | |
| 28,440 | | |
| 26,721 | |
| | |
| | | |
| | |
| Stockholders’ equity | |
| | | |
| | |
| Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding | |
| - | | |
| - | |
| Common Stock, $0.0001 par value per share: 100,000,000 shares authorized, 35,478,123 and 30,738,585 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively | |
| 4 | | |
| 3 | |
| Treasury stock | |
| (25 | ) | |
| (25 | ) |
| Additional paid-in capital | |
| 246,792 | | |
| 217,339 | |
| Accumulated deficit | |
| (225,990 | ) | |
| (179,455 | ) |
| Accumulated other comprehensive income and loss | |
| 34 | | |
| 53 | |
| Total stockholders’ equity attributable to Beyond Air, Inc | |
| 20,814 | | |
| 37,915 | |
| Non-controlling interest | |
| 2,657 | | |
| 4,113 | |
| Total equity | |
| 23,471 | | |
| 42,028 | |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | |
$ | 51,911 | | |
$ | 68,749 | |
BEYOND
AIR, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(amounts
in thousands, except share and per share data)
(UNAUDITED)
| | |
For the Three Months Ended | | |
For the Nine Months Ended | |
| | |
December 31, | | |
December 31, | |
| | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| | |
| | |
| | |
| | |
| |
| Revenue | |
$ | 391 | | |
$ | - | | |
$ | 689 | | |
$ | - | |
| | |
| | | |
| | | |
| | | |
| | |
| Cost of revenue | |
| 748 | | |
| 68 | | |
| 1,483 | | |
| 247 | |
| | |
| | | |
| | | |
| | | |
| | |
| Gross loss | |
| (356 | ) | |
| (68 | ) | |
| (794 | ) | |
| (247 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Research and development | |
| (6,838 | ) | |
| (5,000 | ) | |
| (18,664 | ) | |
| (12,679 | ) |
| General and administrative | |
| (9,768 | ) | |
| (8,941 | ) | |
| (30,915 | ) | |
| (25,144 | ) |
| Operating expenses | |
| (16,606 | ) | |
| (13,941 | ) | |
| (49,578 | ) | |
| (37,823 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Operating loss | |
| (16,963 | ) | |
| (14,010 | ) | |
| (50,372 | ) | |
| (38,070 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Other income (loss) | |
| | | |
| | | |
| | | |
| | |
| Dividend/interest income and gains on marketable securities | |
| 388 | | |
| 271 | | |
| 1,438 | | |
| 388 | |
| Interest expense | |
| (919 | ) | |
| (46 | ) | |
| (1,991 | ) | |
| (142 | ) |
| Change in fair value of warrant liability | |
| 46 | | |
| - | | |
| 693 | | |
| - | |
| Change in fair value of derivative liability | |
| 135 | | |
| - | | |
| 1,147 | | |
| - | |
| Foreign exchange gain | |
| 31 | | |
| 286 | | |
| (3 | ) | |
| (108 | ) |
| Estimated liability for contingent loss | |
| (11 | ) | |
| (248 | ) | |
| (609 | ) | |
| (248 | ) |
| Other Income/ (expense) | |
| 35 | | |
| (52 | ) | |
| (42 | ) | |
| (71 | ) |
| Total other income (expense) | |
| (294 | ) | |
| 211 | | |
| 633 | | |
| (180 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Benefit from income taxes | |
| - | | |
| - | | |
| - | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss | |
$ | (17,258 | ) | |
$ | (13,798 | ) | |
$ | (49,739 | ) | |
$ | (38,250 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Less : net loss attributable to non-controlling interests | |
| (1,038 | ) | |
| (1,051 | ) | |
| (3,204 | ) | |
| (2,601 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss attributable to Beyond Air, Inc. | |
| (16,220 | ) | |
| (12,747 | ) | |
| (46,535 | ) | |
| (35,649 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Foreign currency translation gain /(loss) | |
| (9 | ) | |
| (184 | ) | |
| (19 | ) | |
| 159 | |
| Comprehensive loss attributable to Beyond Air, Inc. | |
$ | (16,229 | ) | |
$ | (12,931 | ) | |
$ | (46,554 | ) | |
$ | (35,490 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net basic and diluted loss per share attributable to Beyond Air, Inc. | |
$ | (0.50 | ) | |
$ | (0.43 | ) | |
$ | (1.46 | ) | |
$ | (1.19 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Weighted average number of shares, outstanding, basic and diluted | |
| 32,462,476 | | |
| 29,921,254 | | |
| 31,883,799 | | |
| 29,902,694 | |
v3.24.0.1
Cover
|
Feb. 12, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Feb. 12, 2024
|
| Entity File Number |
001-38892
|
| Entity Registrant Name |
Beyond
Air, Inc.
|
| Entity Central Index Key |
0001641631
|
| Entity Tax Identification Number |
47-3812456
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
900
Stewart Avenue
|
| Entity Address, Address Line Two |
Suite 301
|
| Entity Address, City or Town |
Garden
City
|
| Entity Address, State or Province |
NY
|
| Entity Address, Postal Zip Code |
11530
|
| City Area Code |
(516)
|
| Local Phone Number |
665-8200
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common
Stock, par value $.0001 per share
|
| Trading Symbol |
XAIR
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Beyond Air (NASDAQ:XAIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Beyond Air (NASDAQ:XAIR)
Historical Stock Chart
From Apr 2023 to Apr 2024
